semaglutide bowel obstruction law office in dallas gastric intestinal firm Ozempic and Wegovy Manufacturers Accused of Downplaying Drugs' Risks in Product Liability Suit Weight Loss Drugs Lawsuit |

doi: 10.2337/db20-89-LB 78 StensenSGasbjergLSKroghLLSkov-JeppesenKSparre-UlrichAHJensenMHet al

Abstract OBJECTIVE These post hoc analyses of the Semaglutide Treatment Effect in People with obesity (STEP) 13 trials (NCT03548935, NCT03552757, and NCT03611582) explored the effects of semaglutide (up to 2.4 mg) on kidney function

This does not happen for everyone, but the pattern is common, especially when weight loss is steady and supported by healthy lifestyle changes

It includes multiple trials studying retatrutide in different populations: TRIUMPH-1 (obesity/overweight without type 2 diabetes, NCT05929066), TRIUMPH-3 (severe obesity + cardiovascular disease, NCT05882045), TRIUMPH-9 (dose-escalation in obesity, NCT07357415), and TRIUMPH-Outcomes (cardiovascular and kidney outcomes in adults with obesity, NCT06383390)

Learn more: Wegovy plateau: Why weight loss stalls and what to do next Can stopping and restarting semaglutide affect results